ArticlePloS one2025
Over-time changes in the prevalence of metabolic syndrome and its components among elderly population in Iran from 2016 to 2021; A nation-wide study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of the VDR rs1544410 Polymorphism with Metabolic Syndrome and Cardiometabolic Traits in Institutionalized Older Adults.International journal of molecular sciences · 2026Article
- Sociodemographic determinants and prevalence of metabolic risk factors and the metabolic syndrome among women aged 20-49 in kirinyaga county, Kenya.Frontiers in epidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of Metabolic Syndrome (MetS) increases with aging, significantly contributing to the rising burden of non-communicable diseases (NCDs). This study aimed to investigate over-time changes in the prevalence of MetS and its components among the elderly population of Iran.
methodsWe analyzed data from the 2016 and 2021 national STEPwise approach to non-communicable disease risk factor Surveillance (STEPS) for participants aged ≥65 who completed all three survey steps (questionnaire-based assessments, physical measurements, and laboratory tests) with no missing data on MetS components. According to the STEPS protocol, individuals with severe mental disorders, physical limitations that prevented measurements, or inability to provide laboratory samples were excluded. Using survey analysis techniques and weights, we ensured the findings are nationally representative. MetS was defined using the following criteria: National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII), International Diabetes Federation (IDF), American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), and Joint Interim Statement (JIS). Regional IDF (RIDF) and regional JIS (RJIS) were defined by ethnicity-specific values of waist circumference.
resultsThis study included 4,000 elderly participants in 2016 and 3,849 in 2021, with a mean age of 74 and 72 years, respectively. Approximately 50% were female in both years, and the proportion of urban residents increased from 67% in 2016 to 75% in 2021. The national prevalence of MetS among the elderly increased significantly from 46.11%-66.38% in 2016 to 54.15%-73.98% in 2021 across different criteria, with an annual percent change of 2.19%-3.26%. Prevalence was higher in females and urban populations, while males showed a greater increase. High blood pressure, low high-density lipoprotein cholesterol, and central obesity were the most common components of MetS, while elevated triglycerides and high fasting plasma glucose showed the largest increases over time.
conclusionsThe escalating prevalence of MetS in the elderly is a matter of increasing concern, underscoring the need for targeted policy interventions aimed at promoting healthy aging, empowering the elderly, and advocating for lifestyle modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.